1
Tarran Jones
Robert W Chestnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Antibodies to P-selectin and their uses. Cytel Corporation, Campbell & Flores, September 1, 1998: US05800815 (24 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


2
Tarran Jones
Robert W Chesnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Method for detecting the presence of P-selectin. Cytel Corporation, Campbell & Flores, March 7, 2000: US06033667 (4 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


3
Marion T Kasaian, Lioudmila Tchistiakova, Geertruida M Veldman, Kimberly Ann Marquette, Xiang Yang Tan, Debra D Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L Wood, Lori J Fitz, Angela M Widom, Kevin D Parris, Samuel J Goldman, Jose W Saldanha: Antibodies against human interleukin-13 and pharmaceutical compositions thereof. Wyeth, Lando & Anastasi, November 10, 2009: US07615213 (20 worldwide citation)

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preve ...


4
Paul D Lyne, Ellen A Garber, Jose W Saldanha, Michael Karpusas: Antibodies to VLA-1. Biogen Idec Ma, Lowrie Lando & Anastasi, April 15, 2008: US07358054 (5 worldwide citation)

Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structur ...


5
Shelia M Violette, Louise A Koopman, Kenneth J Simon, Paul H Weinreb, Herman W T van Vlijmen, Jose W Saldanha, Alexey A Lugovskoy: antibodies and uses thereof, β, Anti-α. Biogen Idec MA, McAndrews Held & Malloy, May 17, 2011: US07943742 (4 worldwide citation)

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also p ...


6
Antonin R De Fougerolles, Victor E Kotelianski, Ellen Garber, Carl Reid, Jose W Saldanha, Herman Van Vlijmen: Humanized antibodies against monocyte chemotactric proteins. Biogen Idec Ma, Finnegan Henderson Farabow Garrett & Dunner L, February 15, 2011: US07888479 (2 worldwide citation)

The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.


7
Antonin R De Fougerolles, Victor E Kotelianski, Ellen Garber, Carl Reid, Jose W Saldanha, Herman Van Vlijmen: Humanized antibodies against monocyte chemotactic proteins. Biogen Idec MA, Finnegan Henderson Farabow Garrett & Dunner, August 27, 2013: US08519112 (1 worldwide citation)

The invention provides humanized antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.


8
Marion T Kasaian, Lioudmila Gennadievna Tchistiakova, Geertruida Machteld Veldman, Kimberly Ann Marquette, Xiang Yang Tan, Debra D Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L Wood, Lori J Fitz, Angela M Widom, Kevin D Parris, Samuel J Goldman, Jose W Saldanha: Antibodies against human interleukin-13 and uses therefor. Wyeth, July 17, 2012: US08221752

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preve ...


9
Shelia M Violette, Louise A Koopman, Kenneth J Simon, Paul H Weinreb, Herman W T van Vlijmen, Jose W Saldanha, Alexey A Lugovskoy: antibodies and uses thereof, β, Anti-α. Biogen Idec MA, Fish & Richardson P C, March 31, 2015: US08992924

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also p ...


10
Gregorio Aversa, Frank Kolbinger, Jose M Carballido Herrera, Andras Aszodi, Jose W Saldanha, Bruce M Hall: Therapeutic binding molecules. Novartis, Corporate Intellectual Property, March 31, 2005: US20050069538-A1

A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Ly ...